Tal Lorberbaum

Tal Lorberbaum

Auto-generated profile, based on publicly available information

Tal Lorberbaum

Department of Physiology and Cellular Biophysics, Columbia University, New York, NY, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2014 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
SVSantiago Vilar
Santiago Vilar
EUEugenio Uriarte
Eugenio Uriarte
LSLourdes Santana
Lourdes Santana
TLTal Lorberbaum
Tal Lorberbaum
GHGeorge Hripcsak
George Hripcsak
NTNicholas P Tatonetti
Nicholas P Tatonetti

18 November 2014 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
TLT Lorberbaum
T Lorberbaum
MNM Nasir
M Nasir
MKMj Keiser
Mj Keiser
SVS Vilar
S Vilar
GHG Hripcsak
G Hripcsak
NTNp Tatonetti
Np Tatonetti
Small molecule drugs are the foundation of modern medical practice, yet their use is limited by the onset of unexpected and severe adverse events (AEs). Regulatory agencies rely on postmarketing surveillance to monitor safety once drugs are approved for clinical use. Despite advances in pharmacovigilance methods that address issues of confounding bias, clinical data of AEs are inherently noisy. Systems pharmacology—the integration of systems biology and chemical genomics—can illuminate drug mechanisms of action. We hypothesize that these data can improve drug safety surveillance by highlighting drugs with a mechanistic connection to the target phenotype (enriching true positives) and filtering those that do not (depleting false positives). We present an algorithm, the modular assembly of drug safety subnetworks (MADSS), to combine systems pharmacology and pharmacovigilance data and significantly improve drug safety monitoring for four clinically relevant adverse drug reactions.

12 November 2015 in WIREs Mechanisms of Disease
Verified
Journal Article
Closed access
PDF file
MBMary Regina Boland
Mary Regina Boland
AJAlexandra Jacunski
Alexandra Jacunski
TLTal Lorberbaum
Tal Lorberbaum
Joseph D. RomanoJoseph D. Romano
Joseph D. Romano
RMRobert Moskovitch
Robert Moskovitch
NTNicholas P. Tatonetti
Nicholas P. Tatonetti

10 February 2016 in Drug Safety
Verified
Journal Article
Open access
PDF file
TLTal Lorberbaum
Tal Lorberbaum
KSKevin J. Sampson
Kevin J. Sampson
RWRaymond L. Woosley
Raymond L. Woosley
RKRobert S. Kass
Robert S. Kass
NTNicholas P. Tatonetti
Nicholas P. Tatonetti
Introduction Drug-induced prolongation of the QT interval on the electrocardiogram (long QT syndrome, LQTS) can lead to a potentially fatal ventricular arrhythmia known as torsades de pointes (TdP). Over 40 drugs with both cardiac and non-cardiac indications are associated with increased risk of TdP, but drug–drug interactions contributing to LQTS (QT-DDIs) remain poorly characterized. Traditional methods for mining observational healthcare data are poorly equipped to detect QT-DDI signals due to low reporting numbers and lack of direct evidence for LQTS. Objective We hypothesized that LQTS could be identified latently using an adverse event (AE) fingerprint of more commonly reported AEs. We aimed to generate an integrated data science pipeline that addresses current limitations by identifying latent signals for QT-DDIs in the US FDA’s Adverse Event Reporting System (FAERS) and retrospectively validating these predictions using electrocardiogram data in electronic health records (EHRs). Methods We trained a model to identify an AE fingerprint for risk of TdP for single drugs and applied this model to drug pair data to predict novel DDIs. In the EHR at Columbia University Medical Center, we compared the QTc intervals of patients prescribed the flagged drug pairs with patients prescribed either drug individually. Results We created an AE fingerprint consisting of 13 latently detected side effects. This model significantly outperformed a direct evidence control model in the detection of established interactions (p = 1.62E−3) and significantly enriched for validated QT-DDIs in the EHR (p = 0.01). Of 889 pairs flagged in FAERS, eight novel QT-DDIs were significantly associated with prolonged QTc intervals in the EHR and were not due to co-prescribed medications. Conclusions Latent signal detection in FAERS validated using the EHR presents an automated and data-driven approach for systematically identifying novel QT-DDIs. The high-confidence hypotheses flagged using this method warrant further investigation.

12 June 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SVSantiago Vilar
Santiago Vilar
TLTal Lorberbaum
Tal Lorberbaum
GHGeorge Hripcsak
George Hripcsak
NTNicholas P. Tatonetti
Nicholas P. Tatonetti
Identification of Drug-Drug Interactions (DDIs) is a significant challenge during drug development and clinical practice. DDIs are responsible for many adverse drug effects (ADEs), decreasing patient quality of life and causing higher care expenses. DDIs are not systematically evaluated in pre-clinical or clinical trials and so the FDA U. S. Food and Drug Administration relies on post-marketing surveillance to monitor patient safety. However, existing pharmacovigilance algorithms show poor performance for detecting DDIs exhibiting prohibitively high false positive rates. Alternatively, methods based on chemical structure and pharmacological similarity have shown promise in adverse drug event detection. We hypothesize that the use of chemical biology data in a post hoc analysis of pharmacovigilance results will significantly improve the detection of dangerous interactions. Our model integrates a reference standard of DDIs known to cause arrhythmias with drug similarity data. To compare similarity between drugs we used chemical structure (both 2D and 3D molecular structure), adverse drug side effects, chemogenomic targets, drug indication classes, and known drug-drug interactions. We evaluated the method on external reference standards. Our results showed an enhancement of sensitivity, specificity and precision in different top positions with the use of similarity measures to rank the candidates extracted from pharmacovigilance data. For the top 100 DDI candidates, similarity-based modeling yielded close to twofold precision enhancement compared to the proportional reporting ratio (PRR). Moreover, the method helps in the DDI decision making through the identification of the DDI in the reference standard that generated the candidate.

16 August 2015 in bioRxiv
Verified
Preprint
Open access
PDF file
TLTal Lorberbaum
Tal Lorberbaum
KSKevin J Sampson
Kevin J Sampson
RWRaymond L Woosley
Raymond L Woosley
RKRobert S Kass
Robert S Kass
NTNicholas P Tatonetti
Nicholas P Tatonetti
Drug-induced prolongation of the QT interval on the electrocardiogram (long QT syndrome, LQTS) can lead to a potentially fatal ventricular arrhythmia called Torsades de Pointes (TdP). 180 drugs with both cardiac and non-cardiac indications have been found to increase risk for TdP, but drug-drug interactions contributing to LQTS (QT-DDIs) remain poorly characterized. Traditional methods for mining observational healthcare data are poorly equipped to detect QT-DDI signals due to low reporting numbers and a lack of direct evidence for LQTS. In this study we present an integrative data science pipeline that effectively circumvents these limitations by identifying latent signals for QT-DDIs in the FDA?s Adverse Event Reporting System and retrospectively validating these predictions using electrocardiogram data in electronic health records. We present 26 novel QT-DDIs flagged using this method that warrant further investigation.